Skip to main content
Premium Trial:

Request an Annual Quote

PathoGenetix Raises $3.6M, Targeting $9.1M

NEW YORK (GenomeWeb News) – Sequencing technology firm PathoGenetix has raised $3.6 million, it said in a regulatory filing.

In the document filed with the US Securities and Exchange Commission on Tuesday, the Woburn, Mass.-based firm said it is targeting $9.1 million in the current offering. The type of securities being offered is in the form of equity. The company did not identify the investors or say how it plans to use the funding.

A company official did not respond to an e-mail requesting comment.

PathoGenetix develops products and applications based on its Genome Sequence Scanning technology, which was originally developed to detect biothreat pathogens in environmental samples. The company is exploring use of the technology for rapid bacterial identification and strain typing in food safety testing, industrial microbiology, and clinical diagnostics, and research.

In late September, it and Applied Math announced an agreement to integrate PathoGenetix's Resolution System and Applied Math's BioNumerics software.

Resolution is slated for a commercial launch during the third quarter of 2014 with assays to identify and serotype Salmonella and pathogenic E. coli strains, a company official told In Sequence recently.

PathoGenetix previously raised $11.5 million in a Series B round in 2011.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.